1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- ALLERGAN
- Biogen
- Novartis
- Teva Pharmaceutical
- MORE
Increase in aging population to drive growth in the market. The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer’s and Parkinson’s disease. The analysts have predicted that the neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.
Market Overview
Availability of highly sensitive diagnostic modalities
The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.
High failure rate of neurodegenerative drugs in clinical trials
There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.
For the detailed list of factors that will drive and challenge the growth of the neurodegenerative diseases therapeutics market during the 2018-2022, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Teva Pharmaceutical, the competitive environment is quite intense. Factors such as the increase in aging population and the availability of highly sensitive diagnostic modalities, will provide considerable growth opportunities to neurodegenerative diseases therapeutics manufactures. ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical are some of the major companies covered in this report.
Market Overview
Availability of highly sensitive diagnostic modalities
The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.
High failure rate of neurodegenerative drugs in clinical trials
There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.
For the detailed list of factors that will drive and challenge the growth of the neurodegenerative diseases therapeutics market during the 2018-2022, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novartis and Teva Pharmaceutical, the competitive environment is quite intense. Factors such as the increase in aging population and the availability of highly sensitive diagnostic modalities, will provide considerable growth opportunities to neurodegenerative diseases therapeutics manufactures. ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- ALLERGAN
- Biogen
- Novartis
- Teva Pharmaceutical
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 11: REGIONAL LANDSCAPE
PART 13: DRIVERS AND CHALLENGES
PART 15: VENDOR LANDSCAPE
Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III development
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global neurodegenerative diseases therapeutics market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global neurodegenerative diseases therapeutics market - Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global neurodegenerative diseases therapeutics market by indication - Market share 2017-2022 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Year over year growth 2018-2022 (%)
Exhibit 23: Global neurodegenerative diseases therapeutics market by others - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global neurodegenerative diseases therapeutics market by others - Year over year growth 2018-2022 (%)
Exhibit 25: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease - Year over year growth 2018-2022 (%)
Exhibit 27: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Year over year growth 2018-2022 (%)
Exhibit 29: Global neurodegenerative diseases therapeutics market by Huntington's disease - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Global neurodegenerative diseases therapeutics market by Huntington's disease - Year over year growth 2018-2022 (%)
Exhibit 31: Market opportunity by indication
Exhibit 32: Customer landscape
Exhibit 33: Global neurodegenerative diseases therapeutics market by region - Market share 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Neurodegenerative diseases therapeutics market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Neurodegenerative diseases therapeutics market in Americas - Year over year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: Neurodegenerative diseases therapeutics market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Neurodegenerative diseases therapeutics market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: Neurodegenerative diseases therapeutics market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Neurodegenerative diseases therapeutics market in APAC - Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Late-stage pipeline for different neurogenerative diseases during 2017-2018
Exhibit 46: Some patent expiries of neurodegenerative diseases in US
Exhibit 47: Some drug failures for neurodegenerative diseases in clinical trials in 2017-2018
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Vendor overview
Exhibit 54: ALLERGAN - Business segments
Exhibit 55: ALLERGAN - Organizational developments
Exhibit 56: ALLERGAN - Geographic focus
Exhibit 57: ALLERGAN - Segment focus
Exhibit 58: ALLERGAN - Key offerings
Exhibit 59: Vendor overview
Exhibit 60: Biogen - Business segments
Exhibit 61: Biogen - Organizational developments
Exhibit 62: Biogen - Geographic focus
Exhibit 63: Biogen - Key offerings
Exhibit 64: Vendor overview
Exhibit 65: Novartis - Business segments
Exhibit 66: Novartis - Organizational developments
Exhibit 67: Novartis - Geographic focus
Exhibit 68: Novartis - Segment focus
Exhibit 69: Novartis - Key offerings
Exhibit 70: Vendor overview
Exhibit 71: Teva Pharmaceutical - Business segments
Exhibit 72: Teva Pharmaceutical - Organizational developments
Exhibit 73: Teva Pharmaceutical - Geographic focus
Exhibit 74: Teva Pharmaceutical - Segment focus
Exhibit 75: Teva Pharmaceutical - Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Pipeline analysis
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Segmentation by indication
- Comparison by indication
- Multiple sclerosis - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Alzheimer’s disease - Market size and forecast 2017-2022
- Parkinson's disease - Market size and forecast 2017-2022
- Huntington's disease - Market size and forecast 2017-2022
- Market opportunity by indication
- Segmentation by drug class
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Biogen
- Novartis
- Teva Pharmaceutical
- List of abbreviations
Exhibit 01: Parent market
Exhibit 02: Global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III development
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global neurodegenerative diseases therapeutics market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global neurodegenerative diseases therapeutics market - Year over year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global neurodegenerative diseases therapeutics market by indication - Market share 2017-2022 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Year over year growth 2018-2022 (%)
Exhibit 23: Global neurodegenerative diseases therapeutics market by others - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Global neurodegenerative diseases therapeutics market by others - Year over year growth 2018-2022 (%)
Exhibit 25: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Global neurodegenerative diseases therapeutics market by Alzheimer’s disease - Year over year growth 2018-2022 (%)
Exhibit 27: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Year over year growth 2018-2022 (%)
Exhibit 29: Global neurodegenerative diseases therapeutics market by Huntington's disease - Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Global neurodegenerative diseases therapeutics market by Huntington's disease - Year over year growth 2018-2022 (%)
Exhibit 31: Market opportunity by indication
Exhibit 32: Customer landscape
Exhibit 33: Global neurodegenerative diseases therapeutics market by region - Market share 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Neurodegenerative diseases therapeutics market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Neurodegenerative diseases therapeutics market in Americas - Year over year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: Neurodegenerative diseases therapeutics market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 39: Neurodegenerative diseases therapeutics market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: Neurodegenerative diseases therapeutics market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 42: Neurodegenerative diseases therapeutics market in APAC - Year over year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Late-stage pipeline for different neurogenerative diseases during 2017-2018
Exhibit 46: Some patent expiries of neurodegenerative diseases in US
Exhibit 47: Some drug failures for neurodegenerative diseases in clinical trials in 2017-2018
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Vendor overview
Exhibit 54: ALLERGAN - Business segments
Exhibit 55: ALLERGAN - Organizational developments
Exhibit 56: ALLERGAN - Geographic focus
Exhibit 57: ALLERGAN - Segment focus
Exhibit 58: ALLERGAN - Key offerings
Exhibit 59: Vendor overview
Exhibit 60: Biogen - Business segments
Exhibit 61: Biogen - Organizational developments
Exhibit 62: Biogen - Geographic focus
Exhibit 63: Biogen - Key offerings
Exhibit 64: Vendor overview
Exhibit 65: Novartis - Business segments
Exhibit 66: Novartis - Organizational developments
Exhibit 67: Novartis - Geographic focus
Exhibit 68: Novartis - Segment focus
Exhibit 69: Novartis - Key offerings
Exhibit 70: Vendor overview
Exhibit 71: Teva Pharmaceutical - Business segments
Exhibit 72: Teva Pharmaceutical - Organizational developments
Exhibit 73: Teva Pharmaceutical - Geographic focus
Exhibit 74: Teva Pharmaceutical - Segment focus
Exhibit 75: Teva Pharmaceutical - Key offerings
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- ALLERGAN
- Biogen
- Novartis
- Teva Pharmaceutical
- MORE
Global Neurodegenerative Diseases Therapeutics Market 2018 -2022
The analyst recognizes the following companies as the key players in the global neurodegenerative diseases therapeutics market: ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in aging population.”
According to the report, one of the major drivers for this market is the availability of highly sensitive diagnostic modalities.
Further, the report states that one of the major factors hindering the growth of this market is the high failure rate of neurodegenerative drugs in clinical trials.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global neurodegenerative diseases therapeutics market: ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in aging population.”
According to the report, one of the major drivers for this market is the availability of highly sensitive diagnostic modalities.
Further, the report states that one of the major factors hindering the growth of this market is the high failure rate of neurodegenerative drugs in clinical trials.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- ALLERGAN
- Biogen
- Novartis
- Teva Pharmaceutical
Note: Product cover images may vary from those shown
